<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911076</url>
  </required_header>
  <id_info>
    <org_study_id>PVX2TACIN17368</org_study_id>
    <nct_id>NCT03911076</nct_id>
  </id_info>
  <brief_title>Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL</brief_title>
  <acronym>PVX-2</acronym>
  <official_title>A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PapiVax Biotech, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PapiVax Biotech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA
           and single IM TA-CIN immunization regimen

        -  To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN
           immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Safety run-in followed by randomized double-blind, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Safety run-in is open label (no control), followed by randomized double-blind, placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients that have cleared HPV16 at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients that have cleared HPV16 at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on maintenance of Human Papillomavirus (HPV) 16 clearance by Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients that have normal cytology at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on regression to cytology with no evidence of intraepithelial lesion or malignancy (NILM) at Month 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>ASC-US</condition>
  <condition>ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial Lesion</condition>
  <condition>LSIL</condition>
  <arm_group>
    <arm_group_label>PVX-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVX-2</intervention_name>
    <description>pNGVL4a-Sig/E7(detox)/HSP70 (naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)</description>
    <arm_group_label>PVX-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBS and PGC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects age 25-70 years with confirmation of ASC-US, ASC-H, or LSIL by
             liquid-based cytology

          2. HIV uninfected

          3. Patients whose cytologic specimen is HPV16+ by Aptima HPV 16 18/45 Genotype Assay

          4. Body Mass Index â‰¤ 32 kg/m2

          5. Hepatitis B surface antigen negative

          6. Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV
             positive

          7. Patients who are able and willing to comply with all study procedures and voluntarily
             sign an informed consent form, and with anticipated availability for the planned
             follow-up period of one year

          8. Patients who are of childbearing potential agree to remain sexually abstinent, use
             methods of contraception (e.g. oral contraception, barrier methods, spermicide,
             intrauterine device (IUD)), or have a partner who is sterile (i.e., vasectomy) through
             6 months.

          9. Patients must have adequate organ function at the time of enrollment as defined by the
             following parameters: white blood cell count &gt;3,000/mcL; lymphocyte number &gt;500/mcL;
             absolute neutrophil count &gt;1,000/mcL; platelets &gt;90,000/mcL; hemoglobin &gt;9 g/dL; total
             bilirubin &lt;3 X the institutional limit of normal; aspartate aminotransferase (AST
             [SGOT]) / alanine aminotransferase (ALT [SGPT]) &lt;3 X the institutional limit of
             normal; creatinine &lt;2.5X the institutional limit of normal.

         10. Histologic diagnosis of &lt;CIN2 upon screening colposcopic examination with mandatory
             ECC, and cervical biopsy(ies) as clinically indicated.

        Exclusion Criteria:

          1. Patients who are attempting pregnancy within 6 months, pregnant, or breastfeeding.

          2. Patients with immunodeficiency, or treatment with immunosuppressive medications

          3. Administration of any blood product within 3 months of enrollment.

          4. Administration of any licensed vaccine within 2 weeks of enrollment (4weeks for
             measles vaccine)

          5. Participation in a study with an investigational compound or device within 30 days of
             signing informed consent.

          6. History of seizures (unless seizure free for 5 years)

          7. Patients with positive serological test for human immunodeficiency virus (HIV).

          8. Previous cancer history within the past 5 years.

          9. Patients who have had chemotherapy, radiation, biological cancer therapy, or other
             investigational agents within 28 days prior to the first dose of study drug.

         10. Patients who have had surgery within 28 days, excluding minor procedures (dental work,
             skin biopsy, etc).

         11. Patients with an uncontrolled intercurrent illness including, but not limited to,
             ongoing, or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

         12. Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic
             lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis
             (MS), ankylosing spondylitis).

         13. Patients with a recognized immunodeficiency disease including cellular
             immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia; patients who have
             acquired, hereditary, or congenital immunodeficiencies; patients being chronically
             treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone
             (ACTH), or systemic corticosteroids

         14. Previous cervical conization or LEEP procedure or previous total hysterectomy due to
             cervical lesions at enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with cervical cytologic diagnosis of ASC-US, ASC-H, or LSIL</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy Wu, MS</last_name>
    <phone>+886282268451</phone>
    <email>wendy@papivax.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissette Molina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Blomer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corpus Christi Women's Clinic (Elligo Health Research, Inc.)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Kirkham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atypical Squamous Cells of the Cervix</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

